Genentech, Inc.

Bayer Pharma Aktiengessellschaft

Bayer Pharma Aktiengesellschaft

Pascal Savy

John Gary Montana

Ulf Bömer

Stephen Colin Price

Nicholas Charles Ray

Hazel Joan Dyke

Ulrich Bothe

Judith Günther

Martin Lange

Mark S Stanley

Karen Williams

Holger Siebeneicher

Reinhard Nubbemeyer

Holger Steuber

Nicole Schmidt

Liang Bao

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs

The invention relates to azabenzothiophenyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzothiophenyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. 

Aza-benzothiophenyl compounds and methods of use

Growing community of inventors

Harlow, United Kingdom

Pascal Savy